- Home
- CCXIU vs KLTOW Comparison
CCXIU vs KLTOW Comparison
Compare CCXIU & KLTOW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
HOLD
Current Price
$0.14
Company Overview
Basic Information| Metric | CCXIU | KLTOW |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | United States |
| Employees | N/A | 3 |
| Industry | Blank Checks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | N/A |
| IPO Year | 2025 | 2022 |
Fundamental Metrics
Financial Performance| Metric | CCXIU | KLTOW |
|---|---|---|
| Price | $10.24 | $0.14 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 16.6K | 12.5K |
| Earning Date | N/A | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.19 | $0.01 |
| 52 Week High | $10.45 | $0.95 |
Technical Indicators
Market Signals| Indicator | CCXIU | KLTOW |
|---|---|---|
| Relative Strength Index (RSI) | 47.24 | 50.20 |
| Support Level | $10.21 | $0.07 |
| Resistance Level | $10.40 | $0.17 |
| Average True Range (ATR) | 0.07 | 0.02 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 20.75 | 32.47 |
Price Performance
Historical Comparison CCXIU
KLTOW
About CCXIU Churchill Capital Corp XI Units
Churchill Capital Corp XI is a blank check company.
About KLTOW Klotho Neurosciences Inc. Warrant
Klotho Neurosciences Inc is in the development of essential medicines for the treatment of chronic diseases: Cancer, Cardiovascular, and Neurodegenerative disorders. The Company currently has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases. Company pipeline includes KLTO 101, KLTO 202, KLTO 301.